San Antonio Breast Cancer Symposium
Carroll Highlights Data Presented at SABCS from the CARRIERS and RIGHT Choice Studies
January 20, 2023
Article
Jamie Carroll, APRN, CNP, MSN, offers her perspective on emerging data from the 2022 San Antonio Breast Cancer Symposium.
Nurse Practitioners Weigh in on Data From the San Antonio Breast Cancer Symposium
January 16, 2023
Podcast
Loyda Braithwaite, MSN, RN, AGPCNP-BC, AOCNP; and Jamie Carroll, APRN, CNP, MSN, highlight presentations from the 2022 San Antonio Breast Cancer Symposium that will influence oncology nursing practice.
Emerging Data Showcases Promising Advancements for Patients With HER2-Low Breast Cancer
January 09, 2023
Article
Loyda Braithwaite, MSN, RN, AGPCNP-BC, AOCNP, reflects on data presented at the San Antonio Breast Cancer Symposium.
Sacituzumab Govitecan Continues to Prolong Survival in Patients With HR+/HER2– Breast Cancer
January 08, 2023
Article
Patients with hormone receptor–positive, HER2-negative metastatic breast cancer derived benefit with sacituzumab govitecan regardless of Trop-2 expression.
POSITIVE Study Findings Shift Conversations on Pregnancy in ER+ Breast Cancer
January 06, 2023
Article
Jamie Carroll, APRN, CNP, MSN, weighs in on how findings from the POSITIVE study may change dialogue surrounding pregnancy for women with estrogen receptor–positive breast cancer who wish to pause adjuvant therapy.
CBD Oil Shows Modest Improvements in Tamoxifen-Related Adverse Effects
January 06, 2023
Article
Cannabidiol oil may be useful in helping patients with breast cancer manage tamoxifen-related adverse effects.
Antidiarrheal Prophylaxis Remains a Key Focus in TKI Treatment for Patients with HER2+ Breast Cancer
January 04, 2023
Article
Loperamide prophylaxis was linked to low rates of grade 3 diarrhea in patients receiving adjuvant pyrotinib, but better antidiarrheal prophylaxis options are still needed in this setting.
Black Women With HR+ Breast Cancer Experience Inferior Outcomes, Despite Comparable Recurrence Scores
January 01, 2023
Article
Non-Hispanic Black patients with hormone receptor (HR)–positive/HER2-negative breast cancer were more likely to have worse outcomes vs non-Hispanic White, Asian, and Hispanic patients, even with similar 21-gene recurrence scores.
Real-World Data Show Neoadjuvant Pertuzumab/Trastuzumab Increases pCR Rates in HER2+ Breast Cancer
December 28, 2022
Article
Neoadjuvant pertuzumab/trastuzumab increased the rate of pathological complete response in patients with HER2-positive breast cancer.
Grace Choong and Matthew Goetz On the Impact of Adjuvant Endocrine Therapy Omission in ER+ Positive Breast Cancer
December 26, 2022
Video
Grace Choong, MD; and Matthew Goetz, MD, discuss the effect of omitting adjuvant endocrine therapy for patients with estrogen receptor–positive breast cancer who were treated with neoadjuvant chemotherapy.